CDKN2A and neoplasm: Paired pre- and on-treatment (cycle 1 week 3) tumor biopsies were collected during the expansion phase to assess changes in expression of DNMT1 and the epigenetically regulated tumor suppressor protein p16 by immunohistochemistry (IHC), as well as changes in genome-wide DNA promoter methylation.